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Plasmodium falciparum malaria is a major human health
scourge and a key cause of mortality. Its pathogenicity partly
results from the phenomenon of “cytoadherence” mediated by
the PfEMP1 (Plasmodium falciparum erythrocyte membrane
protein 1) family. Extracellular domains of PfEMP1s are vari-
able and bind various host endothelial receptors, whereas their
cytoplasmic domains (VARCs) are relatively conserved. VARCs
affix PfEMP1s in the human erythrocytemembrane by interact-
ing with host cytoskeleton proteins and exported parasite pro-
teins. Here, we provide in vitro and in vivo evidence for PfEMP1
phosphorylation (onVARC) and propose an important function
for this modification. Specific inhibitors and enhancers have
been used to identify erythrocytic casein kinase II (CKII) as the
enzyme responsible for VARC modification activity. We have
also delineated probable CKII target residues on VARC, which
mainly reside in an N-terminal acidic cluster. Our data show
that VARC phosphorylation alters its binding to parasite
encoded knob-associated histidine-rich protein (KAHRP).
Finally, we demonstrate reduced cytoadherence of infected
RBCs to endothelial receptors like ICAM-1 andCSA (these con-
tribute to cerebral and placental malaria, respectively) in
response to their CKII inhibition. Collectively, this study fur-
thers our understanding of VARC function, underscores the
importance of erythrocytic CKII in cytoadherence, and suggests
a possible new target for anti-cytoadherence molecules.
Malaria is a global health problem responsible for1 mil-
lion deaths annually (1). Plasmodium falciparum manifests
some of its pathogenicity by the phenomenon of cytoadher-
ence, the binding of infected RBCs2 (iRBCs) to vascular
endothelium and their sequestration in the microvascula-
ture of various organs to avoid splenic clearance. Cytoadher-
ence is mediated by the antigenically diverse PfEMP1 family
of membrane proteins (encoded by var genes), which are
200–350 kDa in size (2, 3).
Each parasite expresses only one of the60 copies of its var
genes and exports it for insertion into the erythrocyte mem-
brane (2, 3), where it clusters over knobs (4). The extracellular
domains of PfEMP1 are variable and interact with a plethora of
receptors (CD36, ICAM-I, CSA, etc.) on host cells (5–7). How-
ever, their C-terminal cytoplasmic domains (VARCs) of 390–
500 amino acids are well conserved and highly acidic (3).
VARCs are known to interact with host cytoskeletal proteins
actin, spectrin, and actin-spectrin junctions (8). Also, these
bind to parasite-encoded KAHRP (8), which forms an essential
and major component of the knob structure (9–11). VARC is
thus believed to anchor PfEMP1 at the membrane of iRBCs by
forming a meshwork of host and parasite proteins that would
aid to strengthen and stabilize the roots of PfEMP1-endothelial
receptor interaction. Waller et al. (12, 13) have mapped the
subdomains of PfEMP1 that interact with KAHRP and vice
versa. Briefly, the histidine-rich subdomain K1A (of KAHRP)
strongly interacts with the C-terminal end of VARC, and the
highly basic subdomain K2A (of KAHRP; pI 10.8) has strong
affinity for the N-terminal end of VARC. Another report had
suggested that the binding between VARC andKAHRP is likely
to be driven by electrostatic interactions (14).
Ultrastructural studies have revealed that knobs are elec-
tron-dense protrusions on the surface of parasitized erythro-
cytes that act as focal points of attachment between sequestered
iRBCs and host endothelia (15). Knobless parasites generated
by disruption of the KAHRP gene (K) are defective in their
ability to cytoadhere under flow conditions, although they are
capable of adhering at normal levels when tested in static assays
(9). Binding competition experiments between knobby (K)
and K infected erythrocytes suggested that K cytoadher-
ence is of higher affinity than that of K parasites (16). This
reduced adhesiveness of knobless parasites can probably be
interpreted as a result of poor anchoring of PfEMP1 to the host
membrane by VARC in the absence of KAHRP. However,
another report attributes these effects to reduced presentation
of PfEMP1 on the surface of knobless iRBCs (17).
Our current studies indicate that PfEMP1 is phosphorylated
on its cytoplasmic tail by erythrocytic CKII. This post-transla-
tional modification activity is reduced by specific CKII inhibi-
tors and increased by polyamines, which act as specific CKII
enhancers. Our biochemical and biophysical data suggest that
phosphorylation may induce small and subtle structural
changes in VARC. We show that the binding of VARC to
KAHRP domains is enhanced significantly upon phosphoryla-
tion. Finally, we provide data to show that cell-permeable CKII
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inhibitors have an impact on cytoadherence of cultured para-
sitized erythrocytes to host receptors. Together, these observa-
tions lead us to hypothesize a model for possible intracellular
events in iRBCs at the time of cytoadhesion and propose a likely
target for anti-cytoadhesionmolecules useful in severemalaria.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Recombinant
Proteins—Full-length VARC (PF08_0141) was PCR-amplified
from 3D7 P. falciparum cDNA using Pfu polymerase and
cloned into pET28a vector. Deletion constructs for VARC
(VARC 1–291, 87–392, and 87–291) were PCR-amplified using
full-length VARC as a template and cloned into pET28a vector.
Residues Thr61, Thr64, Ser65, Ser66, and Ser68 in the VARC
1–291 construct were mutated to alanine by site-directed
mutagenesis using the QuikChange II kit from Stratagene to gen-
erate an N-terminal acidic cluster mutant of VARC 1–291. All
VARC constructs were expressed in B834 cells and purified using
Ni2-nitrilotriacetic acid affinity columns by virtue of their C-ter-
minal hexahistidine tags. The best fractions from affinity chroma-
tography were further purified by anion exchange chromatogra-
phy on Q-Sepharose and then subjected to size exclusion on a
Superdex 75 column fromAmersham Biosciences.
Two domains of KAHRP (K1A and K2A) that interact with
VARC were PCR-amplified from P. falciparum 3D7 cDNA
using Pfu polymerase and cloned into pET28a vector. These
constructs were also expressed in
B834 cells and purified on Ni2-ni-
trilotriacetic acid affinity columns.
The nickel elutes were further puri-
fied by cation exchange chromatog-
raphy on SP-Sepharose and then
subjected to gel filtration on a
Superdex 200 column.
Immunofluorescence Assays—
High titer polyclonal antibodies
were raised against VARC 1–291 in
mice. Thin smears of mature stage
P. falciparum were fixed in ice-cold
methanol for 20 min. These were
blockedwith 5%BSA and then incu-
bated with anti-VARC antibody
(1:1000) for 1 h. After washing with
1 PBST, the slides were incubated
with anti-mouse antibodies (1:2000)
conjugated to fluorescein isothio-
cyanate for 1 h, and treated with 0.1
M DAPI for 5 min. Slides were
againwashed extensively with PBST
and mounted using Antifade rea-
gent (Bio-Rad). The labeled para-
sites were visualized using a fluores-
cence microscope (Nikon) at 40
magnification.
Culturing of Parasites—P. falcip-
arum laboratory strains (3D7,
FCR3-CSA, and ITG-ICAM) were
cultured in RPMI 1640 (Invitrogen)
supplemented with 0.5% Albumax I (Invitrogen) (or 10%
heat-inactivated human serum) using O RBCs in an envi-
ronment containing 5%O2, 5%CO2, and 90%N2. Cultureswere
synchronized by using 5% sorbitol and 65% Percoll using stand-
ard procedures. FCR3-CSA and ITG-ICAM cultures were
panned on CSA and ICAM-1, respectively, to maintain their
binding phenotypes. Briefly, 10 g/ml CSA (or ICAM-1) were
coated overnight on bacteriological Petri plates at 37 °C in a
humidified chamber. Purified trophozoites and schizonts were
then incubated with bound CSA for 1 h with intermittent shak-
ing. The unboundparasiteswere removed by extensivewashing
with incomplete RPMI, and only bound parasites were cultured
further.
Phosphorylation Assays—5 g of VARC was phosphorylated
with uninfected erythrocyte lysates (1 g of total protein) in
kinase buffer (20 mM Tris-HCl, pH 8.0, 2.5 mM MgCl2, and 2.5
mMMnCl2, 1mM sodiumvanadate, and 0.5mM sodium fluoride
supplemented with 5 Ci of [-32P]ATP) at 30 °C for 1.5 h.
Erythrocyte lysates were prepared according to standard pro-
tocols. Briefly, histopaque was used to purify erythrocytes from
venous blood collected fromhealthy human volunteers. Packed
RBCs were lysed by adding an equal volume of hypotonic lysis
solution (10 mM Tris, pH 8.0, 10 mM NaCl). The membrane
fraction was separated from the cytoplasmic fraction by centri-
fuging the lysed cells at 15,000 rpm in Oakridge tubes (SS34
rotor) and collecting the supernatant (cytoplasmic fraction).
FIGURE 1. Expression and characterization of PF08_0141 VARC constructs. a, purified VARC and its dele-
tion constructs (5g each) loaded on 12%SDS-PAGE.M, proteinmolecularweightmarker;A, VARC full-length;
B, VARC 1–291;C, VARC 87–392;D, VARC 87–291. All constructswere affinity-purified usingNi2-nitrilotriacetic
acid columnchromatography, anion-exchangedonQ-Sepharose, and sizedbygel exclusion chromatography.
b, a schematic representation of PfEMP1 organization. The protein comprises an extracellular domain (ECD), a
transmembrane region (TM), and VARC (with its deletion constructs drawn to scale). c, determination of oligo-
meric state of VARC full-lengthusinggel permeation chromatography. VARC full-length andBSAprofiles on an
S200 Superdex column (GE healthcare) are overlapped to show the dimeric nature of VARC. Peaks correspond-
ing to VARC and BSA (dimer and monomer) are labeled. d, immunofluorescence analysis of VARC in mature
trophozoites. Methanol-fixed parasitized erythrocytes reacted with mouse anti-VARC antibody (1:1000), fluo-
rescein isothiocyanate-conjugated anti-mouse antibodies (1:2000), and DAPI (0.1 M). The labeled parasites
were photographed using a fluorescence microscope (Nikon) at 40 magnification. The left panel shows
fluorescence forVARC (green), counterstained fornucleiwithDAPI (blue); the right panel shows the correspond-
ing bright field DAPI.
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The erythrocyte ghosts were repeatedly washed with cold lysis
solution until traces of hemoglobin were no longer visible.
Kinase reactions of uninfected RBC cytosol or membranes in
the absence of recombinant protein, as relevant, were per-
formed in parallel to act as negative controls. The phosphoryl-
ated samples were resolved by 12% SDS-polyacrylamide gel
electrophoresis and autoradiographed. Inhibitors (heparin
(Sigma) and chondroitin sulfate A (CSA), 4,5,6,7-Tetrabromo-
triazole (TBB), 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benz-
imidazole (DMAT), tetrabromocinnamic acid (TBCA), (Cal-
biochem)) and enhancers (Sigma) were added at the desired
final concentrations wherever needed. An in-gel kinase assay
was also performed to confirm the identity of the kinase
responsible for VARC phosphorylation according to published
protocols (18). Recombinant CKII (250 units) and erythrocyte
membranes (50 g of total protein) were electrophoresed on
SDS-polyacrylamide (15%) gels co-polymerized with 1 mg/ml
VARC 1–291 for the assay. Another gel containing 1 mg/ml
BSA was used as a control.
Immunoprecipation of Radiolabeled PfEMP1 from Cultured
Parasites—Cultured 3D7 parasites were radiolabeled with 50
Ci/ml 35S-protein labeling mix (12 h postinvasion rings) or
[32P]orthophosphate (2 h prior to sample collection). Samples
were collected at the specified time points as supernatants of
parasite pellets lysed in a buffer containing 50 mM Tris, pH
8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 2%
SDS. PfEMP1 was immunoprecipitated (using VARC anti-
bodies) from the above samples in NETT buffer (pH 8.1)
using standard protocols, resolved on 6% polyacrylamide
gels, dried, and autoradiographed.
Circular Dichroism and Fluorescence Spectroscopy—VARC
1–291 was phosphorylated using commercial casein kinase II
(New England Biolabs) according to the manufacturer’s
instructions. An identical reaction without ATP was also done,
and this was used as unphosphorylated VARC sample in these
experiments. Phosphorylated and unphosphorylated VARC
were buffer-exchanged into 10 mM sodium phosphate buffer,
pH 8.0. Far UVCD spectra were recorded on Jasco J810 at 25 °C
in a quartz cuvette of 0.2-cm path length between wavelengths
190 and 250 nm, at a scan speed of 200 nm/min over three
accumulations. The fluorescencemeasurementswere recorded
at room temperature in a PerkinElmer LS 50B spectrometer
with the excitation slit of 5 nm and emission slit of 10 nm at a
scan speed of 900 nm/min. The intrinsic tryptophan fluores-
cence spectra of phosphorylated and unphosphorylated pro-
teins were recorded from 310 to 500 nm with excitation at 280
nm. Fluorescence intensities were averaged across four scans.
Chymotrypsin Fingerprinting—A total of 100 g of VARC
1–291was phosphorylated using casein kinase II (New England
Biolabs) in a 100-l reaction. An identical reaction without
ATP was also performed, and this was used as unphosphoryla-
ted VARC sample in the chymotrypsin digestion experiment. A
kinase reaction of commercial CKII (in the absence of VARC
protein) was used as a control to negate bands corresponding to
the enzyme itself. A total of 100 ng of chymotrypsin was
added to the 100 g of VARC and incubated at 37 °C. After
the indicated time points, 10 l of reaction mixture (10 g of
VARC) was taken out from both phosphorylated and
unphosphorylated tubes, and digestion was stopped by add-
ing SDS-polyacrylamide gel loading buffer. The samples
were boiled, resolved by 15% SDS-PAGE and stained with
Coomassie Brilliant Blue R250.
Plate-based Protein-Protein Interaction Studies—A total of
100 ng each of K1A, K2A, actin, and spectrin were coated on
enzyme-linked immunosorbent assay plates overnight at 4 °C.
After blocking with 5% BSA, the coated ligands were allowed to
interact with different amounts of VARC FL (commercial CKII
phosphorylated versus unphosphorylated) in 1 PBS (2%
BSA) for 1 h at 37 °C. The plates were then incubated with
anti-VARC antibodies (1:10,000) followed by anti-mouse
HRPO (1:20,000) for 1 h each. The plates were developed using
1 mg/ml OPD and H2O2 and read at 490 nm.
Static Cytoadherence Assays—Two microliters of CSA (20
g/ml) or ICAM-1 (25 g/ml) in PBS were spotted on 60-mm
bacteriological Petri plates, allowed to adsorb for 2 h at 37 °C in
a humidified chamber, andused for binding assayswith parasite
cultures. PBS and BSA were spotted as negative controls for
both CSA and ICAM-1 binding, whereas CSB and CSC were
also used in CSA-binding assays. These plates were then
blocked overnight with 1% BSA in PBS at 4 °C. Early to middle
trophozoites were treated with 100 M of either of the CKII
inhibitors for 30min and added to the spotted plates in binding
buffer (FCR3-CSA for CSA and ITG-ICAM for ICAM-1, respec-
tively; 1.25 ml at 1% hematocrit, 3% parasitemia). Untreated cul-
tures were used as positive controls to signify 100% binding. The
FIGURE 2.VARCphosphorylation in vitro and in vivo. a, phosphorylation of
VARC FL using erythrocyte cytosol (Cyto panel) andmembrane (Memb panel)
as the source of enzyme. 5 g of recombinant protein was phosphorylated
using uninfected erythrocyte lysates (1 g of total protein each) in kinase
buffer (20 mM Tris-HCl, pH 8.0, 2.5 mM MgCl2, 2.5 mM MnCl2, 1 mM sodium
vanadate, 0.5 mM sodium fluoride supplemented with 5Ci of [-32P]ATP) at
30 °C for 1.5 h. The phosphorylated sampleswere resolved by 12% SDS-PAGE
and autoradiographed. Ct, the reaction minus VARC; E, the reaction plus
VARC. VARC FL is indicated by an arrow, andmultiple bands above and below
relate to phosphorylated erythrocyte proteins. b, autoradiographs of immu-
noprecipitated 35S/32P-labeled PfEMP1 resolved by SDS-PAGE at 16, 22, 32,
and 42 h postinvasion, as indicated. M, protein molecular weight marker; E,
iRBCs; C, uninfected RBCs. Bands corresponding to full-length PfEMP1 are
marked by arrowheads in either panel. Cultured 3D7 parasites were labeled
using 35S-protein labeling mix (35S-labeled panel) or [32P]orthophosphate
(32P-labeled panel) as detailed under “Experimental Procedures.” Samples
were collected 16, 22, 32, and 42 h postinvasion and immunoprecipitated
using VARC antibodies in NETT buffer, resolved on 6% SDS-PAGE, and
autoradiographed.
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plates were rocked intermittently at 37 °C for 1 h, and unbound
erythrocyteswerewashed awaywith binding buffer. Bound eryth-
rocytes were fixed in 1% glutaraldehyde for 20 min, stained with
2%Giemsa for 20min, and scored using aNikonmicroscopewith
a 10 objective. Bound cells were counted from six randomly
selected distinct fields in triplicate spots from three independent
experiments. Results were expressed as percentage binding in
comparison with positive control (no inhibitors added).
Flow-based Cytoadherence Assays—Microslides were coated
for 2 h at 37 °C with ICAM-1 (25 g/ml) or CSA (20 g/ml) in
PBS and blocked overnight with 1% BSA in PBS at 4 °C. Micro-
slides coated with PBS were used as negative controls in these
assays. Parasitized RBCs (1% hematocrit and 3% parasitemia)
were treated for 30 min with a 100 M concentration of each of
the CKII inhibitors. Untreated parasite cultures were used as
positive controls in these experiments to signify 100% binding.
These iRBC suspensions were then flowed over receptor-coated
microslides for a total of 5min, and thenbindingbufferwas flowed
over to removeunbound cells. The flow rate (0.18ml/min) yielded
a wall shear stress of 0.05 pascals, which has been used widely to
mimic wall shear stresses in themicrovasculature. The number of
stationaryor rolling iRBCswas counted in six randomfieldson the
microslides from three independent experiments. Results were
expressed as percentage binding in






(VARC 1–392) of PfEMP1 (PF08_
0141) was cloned and expressed in a
bacterial overexpression system and
purified to homogeneity (Fig. 1a).
Recombinant FL VARC (45 kDa) is
a dimer in solution, as shown by gel
permeation chromatography (Fig.
1c). It migrates between BSA dimer
(132 kDa) and BSA monomer (66
kDa) on an S200 Superdex column.
Due to its flexible nature, the puri-
fied protein degrades rapidly. Disor-
der prediction servers (DisoPred)
predict the first 100 and the last 100
amino acids of FL VARC to be
highly unstable. Therefore, the
VARC 1–291 construct was gener-
ated (Fig. 1a; this construct was rel-
atively more stable), and polyclonal
serum was raised against purified
VARC 1–291 inmice. Immunofluo-
rescence assays on cultured 3D7
parasites using these antibodies
showed a ring fluorescence pattern
characteristic of PfEMP1 protein
(Fig. 1d).
Phosphorylation of PfEMP1 in
Vitro and in Vivo—Since VARC is exposed to the erythrocyte
cytoplasm after being transported to the RBC membrane, we
tested the ability of erythrocyte kinases to phosphorylate FL
VARC. Uninfected RBC extracts (cytosol and membrane; 1 g
of total protein each) were used as the source of enzyme in in
vitro kinase assays. The membrane fraction of RBCs (Fig. 2a,
lane E, Memb panel) could phosphorylate VARC significantly
better than the cytoplasmic fraction (Fig. 2a, lane E, cyto panel)
in these kinase reactions, as indicated by the intensity of the
band corresponding to recombinant VARC. Since the enzyme
responsible for phosphorylation of VARC was present in the
erythrocyte membrane at a higher concentration, all in vitro
phosphorylation reactions involving RBC extracts were hereaf-
ter performed using purified erythrocyte membranes. The
phosphorylation state of PfEMP1 was tested in cultured 3D7
parasites by radioactive labeling using [32P]orthophosphate,
followed by immunoprecipitation of PfEMP1 with VARC anti-
bodies. In order to detect expression of PfEMP1, 35S-labeled
parasiteswere used as a control. Radioactive bands correspond-
ing to the size of full-length PfEMP1 could be observed 22, 32,
and 42 h postinvasion (Fig. 2b, 32P-labeled panel), confirming
the phosphorylation potential of PfEMP1 in vivo. Expression of
FIGURE 3. Identificationof thekinase responsible forVARCphosphorylation.a, effect of variousCKII inhibitors
onVARCphosphorylation. Eachof these lanes showskinase reactions (withorwithout inhibitors) usingerythrocyte
membranes as the source of enzyme, loaded on a 12% SDS-polyacrylamide gel, and autoradiographed. Lane 1,
reactionminus VARC; lane 2, reactionVARC; lane 3, as in lane 2heparin (0.5g/ml); lane 4, as in lane 2 TBB (2
M); lane5, as in lane2DMAT(0.5M); lane6, as in lane2TBCA(0.5M); lane7, VARCphosphorylationusingrCKII
(NewEnglandBiolabs).b and c, effect of enhancers (b, polylysine; c, putrescine and spermine) onVARCphosphoryl-
ation. Kinase reactionswere performedwith the respective concentration of enhancers, loaded on SDS-PAGE, and
autoradiographed.BandintensitiescorrespondingtoVARCFLweremeasuredusing ImageJsoftware. -Foldchange
was calculated considering band intensity of the reaction without any enhancer as 1. The y axis depicts the -fold
change inphosphorylation,whereas thexaxisdepicts theconcentrationofenhancerused.All experiments inband
cwere performed three times in triplicate, and the data here are represented as an average of the same. d, in-gel
kinaseassay toconfirm the identityof thekinase thatphosphorylatesVARC.VARCwasco-polymerized (1mg/ml) in
a 15% SDS-polyacrylamide gel; rCKII and erythrocytemembranes were resolved on this gel. An in-gel kinase reac-
tion, followed by autoradiography revealed a radioactive band of 45 kDa in the erythrocyte membrane (lane
Memb); this corresponds to the size of recombinant CKII catalytic subunit (lane rCKII).
Erythrocytic Casein Kinase II and Cytoadherence
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PfEMP1 was detectable at all four
time points when samples were col-
lected (Fig. 2b, 35S-labeled panel).
Identification of the Kinase
Responsible for Phosphorylation of
VARC—A number of inhibitors
were used in kinase reactions using
erythrocyte membrane as the
source of enzyme to identify the
kinase responsible for VARC
phosphorylation. Staurosporine, a
generic Ser/Thr kinase inhibitor,
and specific CKII inhibitors (hepa-
rin (19), TBB, DMAT, and TBCA)
were found to be effective against
VARC phosphorylation (Fig. 3a)
(data not shown for staurosporine).
Also, various polyamines (polyly-
sine, putrescine, and spermine) that
act as specific enhancers of CKII
activity (20) could increase the
extent of phosphorylation of VARC
in kinase reactions by 25–60%,
characteristic of these molecules
(20) (Fig. 3, b and c). An in-gel kinase
assay identified a protein band of
45 kDa (Fig. 3d, lane Memb) from
erythrocyte membranes to be
responsible for the phosphorylation
function; this corresponds to the
size of catalytic subunit  of CKII
(Fig. 3d, lane rCKII). The control gel
(co-polymerized with BSA) high-
lighted no radioactive bands (data
not shown), ruling out autophos-
phorylation of detected bands.
Identification of Sites for CKII-me-
diated Phosphorylation of VARC—
Bioinformatics-based analysis
(using phosphorylation and kinase
prediction servers) of VARC sug-
gested the presence of several CKII
target sites with high scores in the
protein. Multiple sequence align-
ment (ClustalW) of VARCs from
3D7 was used to check which of
these sites were conserved among
PfEMP1s (Fig. 4a). These analyses
revealed Thr61, Thr64, Ser65, Ser66,
Ser68, and Thr328 as the most prob-
able target residues for phosphoryl-
ation events. In order to verify these
results and determine CKII target
sites, two other deletion constructs
(residues 87–291 and 87–392) (Fig.
1b) were made. Phosphorylation of
each of these constructs using
erythrocyte membrane as the
Erythrocytic Casein Kinase II and Cytoadherence
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enzyme source in kinase reactionswas performed, and the sam-
ples were resolved on SDS-PAGE. Our results show that VARC
FL and VARC 1–291 could get heavily phosphorylated (Fig. 4b,
lanes A and B), whereas VARC 87–291 showed no phosphoryl-
ation (Fig. 4b, lane D). In lane C, a faint radioactive band corre-
sponding to the size of VARC 87–392 could be observed (Fig.
4b). These findings suggest that the CKII target sites are largely
clustered in the first 87 residues of VARC (Thr61, Thr64, Ser65,
Ser66, and Ser68), along with Thr328 being a likely target. Phos-
phorylation of a mutant VARC 1–291, where Thr61, Thr64,
Ser65, Ser66, and Ser68 were changed to alanine by site-directed
mutagenesis, showed significant reduction in its phosphoryla-
tion potential when tested in an in vitro kinase assay (Fig. 4c),
underscoring the importance of this cluster in VARC
modification.
Effect of Phosphorylation on VARC Conformation—CD
spectroscopy studies were performed to study the changes in
secondary structure of VARC 1–291 upon phosphorylation
(Fig. 5a). Characteristic spectra of a protein containing both
 sheets and random coils were obtained. Comparison of CD
spectra of unphosphorylated and phosphorylated VARC
(using commercial CKII) suggested that very small and sub-
tle conformational changes occur in VARC 1–291 upon
kinase treatment (Fig. 5a). The intrinsic tryptophan fluores-
cence of VARC 1–291 (has four tryptophans) in its phospho-
rylated and unphosphorylated states was also measured. Flu-
orescence was enhanced and red shifted (minor) in the case
of phosphorylated VARC 1–291, suggesting solvent expo-
sure of previously buried tryptophans in response to phos-
phorylation (Fig. 5b). Mild proteolysis of phosphorylated
and unphosphorylated VARC 1–291 using chymotrypsin
produced several polymorphic bands (Fig. 5c), again suggest-
ing the likelihood of minor structural changes. As shown in
Fig. 5c, bands 2 and 3 at the 5 min time point and their
corresponding bands at further time points are indicative of
a domain rearrangement. The appearance of bands 1, 4, and
5 at various time points suggests that structural changes
occur in VARC due to phosphorylation.
Strength of VARC Interaction with P. falciparum-encoded
Proteins Is Altered by Its Phosphorylation—K1A and K2A are
domains of KAHRP that strongly interact with VARC (12). The
interaction of FL VARC versus commercial CKII-phosphoryla-
ted FL VARC was quantitatively measured with each of these
KAHRP domains in plate-based binding assays. Phosphoryl-
ated FLVARCbound significantly better to bothK1A andK2A,
as compared with its unphosphorylated form (Fig. 6, a and b).
AlthoughK2A interaction seemed to reach saturation at higher
concentrations of phosphorylated VARC, K1A binding to both
forms of VARC remained appreciably different even at
higher concentrations (Fig. 6, a and b). Since PfEMP1 is teth-
ered to the RBC cytoskeleton via the binding of its cytoplas-
mic domain to actin and spectrin, we also studied the effect
of FL VARC phosphorylation on its binding to these pro-
teins. The effect of VARC phosphorylation on the interac-
tion of either cytoskeleton proteins with VARC was negligi-
FIGURE 4. Identification of CKII target sites on VARC. a, multiple sequence alignment (ClustalW) of VARCs from 3D7 strain of P. falciparum. The gray boxes
show conservation of probable target site residues Thr61, Thr64, Ser65, Ser66, and Ser68. Thr328 (not shown) was also conserved. b, phosphorylation of VARC
constructs (5g)with erythrocytemembrane extracts resolved on 12%SDS-PAGE and autoradiographed.A, VARC full-length; B, VARC 1–291; C, VARC 87–392;
D, VARC 87–291. Ct, kinase reactionminus VARC. Positions of phosphorylated VARC bands are indicated by arrowheads in the respective lanes. c, phosphoryl-
ationof alanine site-directedmutantof VARC1–291at target sites Thr61, Thr64, Ser65, Ser66, andSer68 as comparedwith that ofwild typeVARC1–291.C, reaction
minus VARC; 291, reaction VARC 1–291 (wild type);Mut, reactionmutant VARC.
FIGURE 5. Structural changes in VARCuponphosphorylation. a, far UV CD
spectra of phosphorylated and unphosphorylated VARC. VARC 1–291 was
phosphorylatedwith casein kinase II and buffer-exchanged in 10mM sodium
phosphate buffer (pH 8.0). Spectra were recorded on Jasco J810 at 25 °C in a
quartz cuvette of 0.2-cm path length betweenwavelengths 190 and 250 nm,
at a scan speed of 200 nm/min over three accumulations, after subtraction of
buffer spectra. The spectrum indicated by a heavy line corresponds to
unphosphorylated VARC, whereas the spectrum indicated with a dotted line
corresponds to phosphorylated VARC. b, tryptophan fluorescence spectra of
phosphorylated and unphosphorylated VARC. The intrinsic tryptophan fluo-
rescence spectra of phosphorylated and unphosphorylated proteins were
recorded from 310 to 500 nmwith excitationwavelength at 280 nm. Fluores-
cence intensities are the average of four scans. The spectrum indicated by a
heavy line corresponds to unphosphorylated VARC, whereas the spectrum
indicatedwith a dotted line corresponds to phosphorylated VARC. c, chymot-
ryptic fingerprinting of phosphorylated VARC. This digestion was performed
for indicated times in identical sets for phosphorylated and unphosphoryla-
ted VARC, as indicated under “Experimental Procedures.” Lanes labeled U and
P represent unphosphorylated and phosphorylated VARC, respectively, fol-
lowed by the indicated time point (min). Lane C, a control for casein kinase II
digestion with chymotrypsin. Arrows 1, 4, and 5 indicate the appearance of
new bands, whereas arrows 2 and 3 suggest domain rearrangement in
response to phosphorylation.
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ble, as depicted by the contiguous concentration-dependent
binding curves (Fig. 6, c and d).
CKII Inhibition Affects Cytoadherence in Cultured Parasites—
Since phosphorylation of VARC increases its affinity for
KAHRPdomains andVARC-KAHRP interactionhas been con-
sidered as an important parameter in cytoadherence, we tested
the effect of a set of cell-permeable CKII inhibitors on cytoad-
hesion to soluble endothelial receptors. The binding reduction
was scored as follows: 0–25%, low; 25–50%, moderate; 50%,
high. The effect of these inhibitors on cytoadherence in static
conditions was low to moderate (Fig. 7, a–c, granulated gray
bars) except in the case of TBB on ITG-ICAM (55% reduc-
tion; Fig. 7a, ICAM-1 panel). However, under flow conditions,
the decline in iRBC binding to ICAM-1/CSA in response to
CKII inhibitors ranged frommoderate to high (Fig. 7, a–c, solid
gray bars).
DISCUSSION
VARCs are the cytoplasmic domains of the PfEMP1 family of
proteins, which are unique to P. falciparum. These domains are
central to the phenomenon of cytoadherence, a major contrib-
utor to P. falciparummalaria-related deaths. VARCs are likely
to be involved in events downstreamor upstreamof host recep-
tor engagement by the N termini of PfEMP1, making them
important and interesting to work
on. Here, we have characterized a
VARC (PF08_0141) as an example
and assigned an important function
to these domains. Full-length
recombinantly expressed VARC is
highly soluble and forms a dimer in
solution, as determined by gel per-
meation chromatography (Fig. 1c).
Deletion constructs of this domain
that are truncated at the amino (res-
idues 87–291 and 87–392) or car-
boxyl termini (residues 1–291) also
run as dimerswhen subjected to size
exclusion (data not shown), imply-
ing that the minimal dimerization
unit lies within the central portion
of the protein. Circular dichroism of
full-length VARC revealed that this
protein is largely composed of
-sheets and random coils (data not
shown).
Since VARCs are cytoplasmic
within the RBC, they are likely to
serve as an important link between
the extracellular cues and erythro-
cytic responses. Protein phospho-
rylation constitutes a major mecha-
nism by which cellular processes
like metabolism, signal transduc-
tion, cell polarity, and cytoskeletal
reorganization can be controlled
(21). The erythrocyte cytoskeleton
is a meshwork of various proteins
that interact with each other and regulate important cellular
functions. Many RBC membrane proteins are subjected to
phosphorylation by the action of erythrocytic kinases (22–25),
sometimes even by constitutive association (26). During their
growth within the red cells, malaria parasites export a number
of their proteins to the RBC membrane (e.g. PfEMP1 and
KAHRP), which hereafter are treated by the cell as their own
(27). This penetration by Plasmodium into the host system
therefore imparts the parasite exported proteins the ability to
interact with erythrocytic molecules (e.g. kinases). Keeping this
in mind, we tested the phosphorylation potential of VARC in
vitro using erythrocyte extracts. We found that erythrocyte
ghosts could efficiently phosphorylate recombinant full-length
and 1–291VARC, whereas the cytosolic kinases had little effect
on VARC (Fig. 2a). Modification of a “pseudomembrane” pro-
tein by proximal erythrocytic membrane kinases may facilitate
the parasites’ purpose to undergo phosphorylation. We have
also shown that full-length PfEMP1 is phosphorylated in vivo.
Although expression of this protein can be seen in cultured
parasites (35S-labeled) as early as 16 h postinvasion, its phos-
phorylated form (32P-labeled) is detectable only as the culture
progresses to its mature stages (22 h postinvasion onward),
whenPfEMP1 is exported to the erythrocyte surface (it iswidely
FIGURE 6. Effect of VARC phosphorylation on its interaction with parasite and host proteins. Binding of
different amounts of unphosphorylated andphosphorylatedVARC to K1A (a), K2A (b), actin (c), and spectrin (d)
is shown. 100 ng of individual proteins K1A, K2A, actin, and spectrin were coated on enzyme-linked immu-
nosorbent assay plates and allowed to interact with different amounts of phosphorylated and unphosphoryl-
ated VARC. Concentration-dependent binding curveswere plotted, as indicated. The y axis represents binding
(measured as absorbance at 490 nm),whereas the x axis represents VARC concentration (unphosphorylated or
phosphorylated, as indicated on the respective curves). Each experiment was performed in triplicate, and the
average of three experiments was plotted after deducting background signal from the negative control (BSA).
The error bars represent the S.D. among the three replicates.
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believed that export of PfEMP1 to RBC surface is effected in the
16–20 h postinvasion window (Fig. 2b).
We have identified CKII as the enzyme responsible for this
post-translational modification by using specific inhibitors
{heparin (19), TBB, DMAT, and TBCA} and enhancers (poly-
amines) (20) in kinase assays (Fig. 3, a–c). Polyamines like
spermine, putrescine, and polylysine are known to stimulate
CKII by causing an aggregation of the substrate, thereby
increasing its effective concentration (28). An in-gel kinase
assay for VARC to identify the responsible enzyme (in erythro-
cytemembranes) highlights a band corresponding to the size of
the catalytic subunit  of CKII (Fig. 3d). This enzyme is a ubiq-
uitously expressed (in all tissues and organisms) and probably
constitutively active Ser/Thr kinase that is located in nearly all
subcellular compartments (29). The erythrocytemembrane has
a distinct pool of CKII, which along with the cytosolic pool
phosphorylates most of the cytoskeletal proteins, including
spectrin, ankyrin, and adducin (23, 26, 30). Our bioinformatics
analysis to identify the target residues for phosphorylation
alongwith the kinasing data ofN- andC-terminal deletion con-
structs suggests thatmost CKII target sites onVARC exist in an
N-terminal acidic cluster, typical of CKII recognition sites (Fig.
4, a and b). A variant of VARC 1–291, where the N-terminal
acidic cluster has been mutated by alanine site-directed
mutagenesis, shows significantly reduced phosphorylation
capability in kinase assays using erythrocyte membranes (Fig.
4c). Another isolated residue of VARC that is likely to undergo
phosphorylation is Thr328, which lies on its C terminus. Our
results imply that VARC harbors multiple phosphorylation
sites for its modification within the RBC. CKII-mediated phos-
phorylation of various proteins is known to change their con-
formation upon modification (31, 32). Our data suggest that
VARCundergoes subtle conformational alterations uponphos-
phorylation (Fig. 5).
Phosphorylation of erythrocyte cytoskeletal proteins alters
their binding affinity for each other, which has important impli-
cations in cellular function (23, 26, 30). VARC is known to
tether PfEMP1 to the RBC cytoskeleton by interacting with
host proteins actin and spectrin and parasite encoded KAHRP.
Here, we have shown that phosphorylation of VARC has a con-
siderable impact on its interaction with KAHRP domains K1A
and K2A, whereas the effect on resident host proteins (actin
FIGURE 7. Effect of CKII inhibitors on cytoadherence. The effect of TBB (a), DMAT (b), and TBCA (c) on binding of FCR3-CSA to CSA (CSA panels) and ITG-ICAM
to ICAM-1 (ICAM-1 panels). Parasitized RBCs were treated for 30 min with a 100M concentration of each of the CKII inhibitors, as indicated. iRBC suspensions
(1% hematocrit and 3% parasitemia) were flowed over receptor-coated microslides for 5 min. The flow rate was set to 0.18 ml/min. The number of stationary
or rolling iRBCs was counted in six random fields on the microslides from three independent experiments. Results were expressed as percentage binding in
comparisonwith untreated culture (100%binding).Microslides coatedwith PBSwere used as negative controls in these assays.Granulated gray bars represent
data from static assays, whereas solid gray bars represent data from flow assays.
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and spectrin) is negligible. Our results depict that upon phos-
phorylation of VARC, its binding to K1Awas alteredmore dra-
matically than to K2A (Fig. 6, a and b). Since K1A interacts with
the C terminus of VARC, it is probable that Thr328 phosphoryl-
ation confers a greater structural change in VARC, as opposed
tomodification of theN terminus, which is known to bindK2A.
Although spectrin is also a substrate for CKII in vivo, we have
observed that its phosphorylation does not have any effect on
VARC-spectrin association (data not shown).
Previous reports suggest that VARC-KAHRP interaction is
central to cytoadherence. Therefore, a change in their binding
strength for each other is likely to reflect on how well iRBCs
cytoadhere. We have studied cytoadhesion abilities of cultured
parasites treated with commercially available, cell-permeable,
and specific CKII inhibitors (33). All three inhibitors used in
this study reduce CKII mediated phosphorylation by compet-
ing for the enzyme’s ATP binding pocket. The effect of these
inhibitors on cytoadherence in static conditions was mostly
insignificant (Fig. 7, a (CSA panel), b, and c), with the exception
of TBB on ITG-ICAM (55% reduction; Fig. 7a, ICAM-1
panel). However, under flow conditions, the decline in iRBC
binding to ICAM-1/CSA in response to CKII inhibitors was
significant (Fig. 7, a–c). Notably, TBCA reduces binding on
ICAM-1 by 75% (Fig. 7c), DMAT on CSA by 65% (Fig. 7b), and
TBB on ICAM-1 by 55% (Fig. 7a). Binding of PfEMP1s to host
receptors like CSA and ICAM-1 is considered important in
severe placental and cerebral malaria, respectively. Our data
show that CKII inhibition causes parasitized RBCs to cytoad-
heremoreweakly to soluble receptors under flow conditions, as
compared with static conditions. On the basis of these results,
we propose the following. Due to a decline in VARC phospho-
rylation and hence weaker binding to KAHRP, it is probable
that PfEMP1 is inadequately anchored to the erythrocyte
cytoskeleton, impairing cytoadherence in circulation. On the
other hand, binding of PfEMP1s to their respective host endo-
thelial receptors is not challenged in the absence of physiolog-
ical shear stress (i.e. static assays). Due to the universal require-
ment of CKII in cellular functions, one could argue that the
enzyme’s inhibition could be lethal to the parasite. However,
the capability of dead parasites to cytoadhere equals that of live
parasites.3 Nonetheless, a possibility that CKII inhibition pro-
duces a more generic effect on iRBC morphology to alter their
cytoadherence properties cannot be ruled out.
Due to polyamine biosynthesis or increased uptake of putres-
cine from the extracellular pool (34, 35), mature stage iRBCs
have significantly elevated levels of polyamines as compared
with uninfected or ring stage parasites. This probably acts in
favor of parasites so that they can utilize their resources to
increaseVARCphosphorylation and cytoadhere better in order
to evade host response. The presence of several polylysine
stretches in KAHRPmay be a parasite’s evolutionary attempt to
enhance VARC phosphorylation and strengthen its roots.
Phosphorylation of major cytoskeletal proteins, such as
ankyrin, band 4.1, and band 4.9, can weaken the rigidity of the
cytoskeleton by reducing the binding affinity of these compo-
nents (24, 26). This property of the erythrocytes is extremely
important, since it regulates membrane deformability essential
for passage through microvasculature. Although the precise
mechanisms leading to decreased deformability of iRBCs are
poorly understood, the contribution of parasite proteins to
increased membrane rigidity is most likely attributable to their
direct or indirect interactions with proteins of the RBC mem-
brane skeleton or other exported parasite proteins (36, 37).
Since phosphorylation of VARC increases its affinity for
KAHRP, it could be one of the factors for increased membrane
rigidity of P. falciparum-infected RBCs.
Since cytoadhesion is a major mechanism by which P. falcip-
arum implements its pathophysiology, drugs that potentially
diminish cytoadherence are considered important agents in the
fight against virulent malaria. This is the first report where
small molecule CKII inhibitors have been assessed for their
anti-cytoadherence activity by targeting intracellular events.
This study suggests that molecules that block or reverse the
interaction between VARC and its binding partners have the
ability to reduce cytoadherence and may therefore be effective
against severe malaria. The CKII target site on VARC presents
itself as a potential new target for development of anti-cytoad-
herence agents. Finally, therapeutics that act to suppress the
molecular functions of conserved VARCs are likely to have an
edge over the ones that aim at abrogating the variable extracel-
lular PfEMP1-host receptor interactions.
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